Al Sandrock, Voyager Therapeutics CEO

Af­ter 12 months of dig­ging, Pfiz­er opts for one of two Voy­ager cap­sids for gene ther­a­py

The path at Voy­ager Ther­a­peu­tics keeps wind­ing, and at the 12-month dead­line, Pfiz­er has elect­ed to on­ly move for­ward with one of two cap­sids out of the pre­clin­i­cal biotech for the Big Phar­ma’s AAV gene ther­a­pies.

Last Oc­to­ber, the Big Phar­ma and biotech linked arms on a deal that gave Pfiz­er the abil­i­ty to hit the gas ped­al on two cap­sids: one for a car­diac tar­get and the oth­er for a rare neu­ro­log­ic dis­ease tar­get.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.